Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
A triple combination targeting epigenetic dysregulation and apoptotic resistance, comprising iadademstat (LSD1 inhibitor), azacitidine (a hypomethylating agent), and venetoclax (a BCL-2 inhibitor), is under investigation in a phase I trial for acute myeloid leukemia (NCT06357182)
10.1007/s12026-025-09634-5 2 AbelliJ.Mndez-ValdsG.Gmez-HeviaF.BragatoM
It has not been evaluated by the Food and Drug Administration (FDA) and is not intended to diagnose, treat, cure, or prevent any disease or medical condition
Detailed Description BPC-157 , also known as Body Protection Compound-157, is a synthetic pentadecapeptide (15 amino acids) derived from a naturally occurring protein in gastric juice
How to Pay: Financing, HSA/FSA, and Insurance Cherry financing: from $17 per month Perfect B offers flexible financing through Cherry, a healthcare financing platform with no hard credit inquiry on the initial application
Anti-inflammatory effects are often reported within the first week
US$ 24.42
,aspect=ignore)
US$ 20.41
US$ 24.87
US$ 29.08
US$ 22.00
US$ 29.37
